Novolog Mix 70-30 Flexpen (Insulin Aspart Prot/Insuln Asp) — Medicare Part D spending
Multiple manufacturers (2) · Rank #155 by total Part D spend · CMS data year 2023
Medicare Part D spent $335,124,166 on Novolog Mix 70-30 Flexpen (Insulin Aspart Prot/Insuln Asp) in 2023, the #155 drug by total Part D spending out of 3,598 drugs. That worked out to about $38.70 per dosage unit, $1,231 per claim and $5,392 per beneficiary, across 272,276 claims for 62,157 beneficiaries. Average spending per dosage unit rose +1.0% from 2022. These are aggregate Medicare program figures (gross drug cost), not the price you pay.
Source: CMS Medicare Part D Spending by Drug (data year 2023). Data as of June 2026.
Novolog Mix 70-30 Flexpen (Insulin Aspart Prot/Insuln Asp) spending at a glance (2023)
| Metric | Novolog Mix 70-30 Flexpen (Insulin Aspart Prot/Insuln Asp) |
|---|---|
| Total Part D spending (2023) | $335,124,166 |
| Total spending (2022) | $357,828,485 |
| Year-over-year change in total spending | -6.3% |
| Average spending per dosage unit (2023) | $38.70 |
| Change in spend per dosage unit (YoY) | +1.0% |
| Avg annual change per dosage unit (2019-2023 CAGR) | +0.8% |
| Average spending per claim (2023) | $1,231 |
| Average spending per beneficiary (2023) | $5,392 |
| Total claims (2023) | 272,276 |
| Beneficiaries (2023) | 62,157 |
| Total dosage units (2023) | 8,644,591 |
| Manufacturer(s) | Multiple manufacturers (2) |
| National rank by total spend (of 3,598 drugs) | #155 |
Source: CMS Medicare Part D Spending by Drug (data year 2023). Data as of June 2026.
2022 vs 2023
| Metric | 2022 | 2023 | Change |
|---|---|---|---|
| Total spending | $357,828,485 | $335,124,166 | -6.3% |
| Avg spend per dosage unit | $38.32 | $38.70 | +1.0% |
| Avg spend per claim | $1,203 | $1,231 | — |
| Avg spend per beneficiary | $5,429 | $5,392 | — |
| Total claims | 297,367 | 272,276 | — |
| Beneficiaries | 65,912 | 62,157 | — |
How Novolog Mix 70-30 Flexpen compares with nearby drugs
Drugs with total Part D spending closest to Novolog Mix 70-30 Flexpen (Insulin Aspart Prot/Insuln Asp):
| Drug (rank) | Total spend 2023 | Per dosage unit | Per-unit YoY |
|---|---|---|---|
| Novolog Mix 70-30 Flexpen (Insulin Aspart Prot/Insuln Asp) (this drug, #155) | $335,124,166 | $38.70 | +1.0% |
| Synthroid (Levothyroxine Sodium) (#153) | $355,295,646 | $1.14 | +9.0% |
| Aubagio (Teriflunomide) (#154) | $353,934,133 | $320.81 | +6.6% |
| Lisinopril (#156) | $331,855,070 | $0.12 | +21.4% |
| Gattex (Teduglutide) (#157) | $330,401,875 | $35,921.06 | +0.4% |
| Aimovig Autoinjector (Erenumab-Aooe) (#158) | $326,938,686 | $778.19 | +6.3% |
Frequently asked questions
How much does Medicare Part D spend on Novolog Mix 70-30 Flexpen?
Medicare Part D spent $335,124,166 on Novolog Mix 70-30 Flexpen (Insulin Aspart Prot/Insuln Asp) in 2023 (the latest CMS data year), across 272,276 claims for 62,157 beneficiaries. That ranks #155 of 3,598 drugs by total Part D spending. This is gross drug cost (Medicare, plan and beneficiary payments combined), not the price you personally pay.
What is the average spending per dosage unit for Novolog Mix 70-30 Flexpen?
In 2023, the weighted average Medicare Part D spending per dosage unit for Novolog Mix 70-30 Flexpen (Insulin Aspart Prot/Insuln Asp) was $38.70. Compared with 2022 it rose +1.0%. A "dosage unit" is one pill, tablet, milliliter or other billing unit, so this is not the price of a prescription.
Who makes Novolog Mix 70-30 Flexpen?
CMS attributes Novolog Mix 70-30 Flexpen (Insulin Aspart Prot/Insuln Asp) to Multiple manufacturers (2) in the 2023 Part D spending file. Average spending per claim was $1,231 and per beneficiary $5,392.
Is the Novolog Mix 70-30 Flexpen figure the price I pay?
No. These are aggregate Medicare Part D program figures (total gross drug cost and averages across all claims), published by CMS for transparency. Your out-of-pocket cost depends on your plan, formulary, deductible and coverage phase. Always check your plan and talk to your pharmacist or doctor.
Keep exploring
Source & what this means
Figures are from the CMS Medicare Part D Spending by Drug dataset (data year 2023, US public domain). "Total spending" is the gross drug cost — Medicare, plan and beneficiary payments combined — for Part D claims; it is not a list price, a negotiated price, or what any individual pays. Spending per dosage unit is volume-weighted across formulations. This is general public-spending information, not medical or pricing advice. Your own cost depends on your plan, deductible and coverage phase — verify with your Part D plan and a pharmacist. Data as of June 2026. See our methodology and disclaimer.
Last updated: 2026-06-20